PROM1 and ovarian cancer: In light of the known correlation of L1CAM with ovarian cancer aggressiveness [61,62], these findings, once confirmed in patient-derived tissue, might implicate L1CAM/CD133-positive CSC in the malignant properties of this tumor type.